BRAF and non-small cell lung carcinoma: Some of these drugs like gefitinib, erlotinib, and crizotinib were explicitly designed to inhibit primary therapeutic targets for NSCLC like the epidermal growth factor receptor (EGFR)5, anaplastic lymphoma receptor tyrosine kinase (ALK)6 and serine/threonine-protein kinase B-Raf (BRAF)7.